Literature DB >> 27497813

The modulatory effect of nitric oxide in pro- and anti-convulsive effects of vasopressin in PTZ-induced seizures threshold in mice.

Nina Javadian1, Nastaran Rahimi1, Mehrak Javadi-Paydar2, Amir Hossein Doustimotlagh3, Ahmad Reza Dehpour4.   

Abstract

Vasopressin neuropeptides play an important role in the several cognitive, social, and neuroendocrine functions. Also, several studies report the involvement of nitrergic system in the vasopressin functions in central nervous system. This study investigates the effect of Arginine-Vasopressin (AVP) in pentylenetetrazol (PTZ)-induced seizures threshold and the probable role of nitric oxide (NO). AVP is administered intraperitoneally (0.01-20μg/kg, i.p.) 30min before induction of seizures. Administration of AVP (0.1μg/kg) significantly lowered the PTZ-induced seizures threshold. But, administration of AVP (10 and 20μg/kg) increased the seizures threshold, significantly. Pretreatment of SR 49059 (V1a receptor antagonist, 2mg/kg, i.p.) just reversed the pro-convulsant effect of AVP. Meanwhile, SSR 149415 (V1b receptor antagonist, 10mg/kg, i.p.) pretreatment reversed both pro-and anti-convulsant effects of AVP. The nitric oxide precursor, L-arginine (60mg/kg, i.p.) increased pro-convulsant effect of AVP, but did not change anticonvulsant activity. The nitric oxide synthase (NOS) inhibitor L-NAME (10mg/kg, i.p.) reversed both pro- and anti-convulsant effect of AVP. Selective inducible NOS inhibitor, aminoguanidine (100mg/kg, i.p.) just reversed the anti-convulsant effects of AVP. The results of the present study showed nitric oxide system may contribute to the biphasic effects of AVP on PTZ-induced seizures. V1a receptor may modulate only the proconvulsive effect. While, V1b receptors can mediate both the pro- and anti-convulsive effect of AVP.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Mice; Nitric oxide; SR 49059; SSR 149415; Seizures; Vasopressin

Mesh:

Substances:

Year:  2016        PMID: 27497813     DOI: 10.1016/j.eplepsyres.2016.07.006

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  6 in total

1.  Effects of oleuropein on pentylenetetrazol-induced seizures in mice: involvement of opioidergic and nitrergic systems.

Authors:  Nastaran Rahimi; Bahram Delfan; Nazgol Motamed-Gorji; Ahmad R Dehpour
Journal:  J Nat Med       Date:  2017-01-19       Impact factor: 2.343

2.  Genistein modulation of seizure: involvement of estrogen and serotonin receptors.

Authors:  Saeed Amiri Gheshlaghi; Razieh Mohammad Jafari; Mohammad Algazo; Nastaran Rahimi; Hussein Alshaib; Ahmad Reza Dehpour
Journal:  J Nat Med       Date:  2017-04-24       Impact factor: 2.343

3.  Effects of Modafinil on Clonic Seizure Threshold Induced by Pentylenetetrazole in Mice: Involvement of Glutamate, Nitric oxide, GABA, and Serotonin Pathways.

Authors:  Erfan Bahramnjead; Soheil Kazemi Roodsari; Nastaran Rahimi; Payam Etemadi; Iraj Aghaei; Ahmad Reza Dehpour
Journal:  Neurochem Res       Date:  2018-08-25       Impact factor: 3.996

Review 4.  New techniques, applications and perspectives in neuropeptide research.

Authors:  Kellen DeLaney; Amanda R Buchberger; Louise Atkinson; Stefan Gründer; Angela Mousley; Lingjun Li
Journal:  J Exp Biol       Date:  2018-02-08       Impact factor: 3.312

5.  Effect of Lenalidomide on Pentylenetetrazole-Induced Clonic Seizure Threshold in Mice: A Role for N-Methyl-D-Aspartic Acid Receptor/Nitric Oxide Pathway.

Authors:  Elaheh Asgari Dafe; Nastaran Rahimi; Nina Javadian; Pegah Dejban; Monika Komeili; Sepideh Modabberi; Mehdi Ghasemi; Ahmad Reza Dehpour
Journal:  J Epilepsy Res       Date:  2021-06-30

6.  Metformin attenuates oxidative stress and liver damage after bile duct ligation in rats.

Authors:  Heibatollah Sadeghi; Fatemeh Jahanbazi; Hossein Sadeghi; Navid Omidifar; Behnam Alipoor; Esmaeel Panahi Kokhdan; Seyed Mehdi Mousavipoor; Seyed Hossein Mousavi-Fard; Amir Hossein Doustimotlagh
Journal:  Res Pharm Sci       Date:  2019-03-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.